The Use of Liraglutide in Brain Death

Conditions

• Brain Death

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• Liraglutide — DRUG
  liraglutide 3mg 6/6 hours

Study Details

There is evidence of the association of brain death and inflammation, affecting outcomes of transplanted organs, but in a way not fully understood. Observational studies suggest that the use of target-guided therapies has a beneficial effect in reducing the rate of donor loss due to cardiac arrest and increasing the rate of donor-picked organs, which will be tested through the randomized clinical trial. However, no study so far has directly tested the effect of drugs with anti-inflammatory and anti-apoptotic properties administered to the donor in encephalic death in reducing inflammation of organs to be transplanted. This study aims to evaluate the use of liraglutide in patients with brain death in relation to their ability to attenuate the inflammation induced by encephalic death by means of a randomized clinical trial.

Key Dates

Start date

Sep 1, 2018

Status verified

Mar 2024

Primary completion

Dec 10, 2019

Completion

Feb 10, 2022

Study Design

Enrollment

50 participants (actual)

Allocation

RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Arms

• No Intervention: placebo
  0,5ml
• Experimental: liraglutide
  0,5ml

Primary Outcome Measure

change inflammation [ Time Frame: from 6 hours to 24 hours ]